ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice

European Urology

Volumn 56, Issue 2, 2009, Pages 275-286

  Tomlins, Scott A ^a   Bjartell, Anders ^b   Chinnaiyan, Arul M ^a,c   Jenster, Guido ^d   Nam, Robert K ^e   Rubin, Mark A ^f   Schalken, Jack A ^g  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f WEILL CORNELL MEDICAL CENTER   (United States)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Early diagnosis; ETS gene fusions; Prostate cancer; TMPRSS2

Indexed keywords

ABIRATERONE ACETATE; MEMBRANE PROTEIN; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ETS; TRANSMEMBRANE PROTEASE SERINE 2; UNCLASSIFIED DRUG;

CANCER SCREENING; CHROMOSOME REARRANGEMENT; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG MECHANISM; EARLY DIAGNOSIS; GENE EXPRESSION; GENE FUNCTION; GENE FUSION; GENETIC TRANSCRIPTION; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN LOCALIZATION; REVIEW;

HUMANS; MALE; ONCOGENE FUSION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS;

EID: 67649425225     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.04.036     Document Type: Review

References (84)

1. Mitelman F., Johansson B., and Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7 (2007) 233-245
2. Deininger M., Buchdunger E., and Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
3. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
4. Seth A., and Watson D.K. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41 (2005) 2462-2478
5. Tomlins S.A., Mehra R., Rhodes D.R., et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66 (2006) 3396-3400
6. Helgeson B.E., Tomlins S.A., Shah N., et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 68 (2008) 73-80
7. Han B., Mehra R., Dhanasekaran S.M., et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 68 (2008) 7629-7637
8. Maher C.A., Kumar-Sinha C., Cao X., et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 458 (2009) 97-101
9. Rickman D.S., Pflueger D., Moss B., et al. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 69 (2009) 2734-2738
10. Iljin K., Wolf M., Edgren H., et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66 (2006) 10242-10246
11. Setlur S.R., Mertz K.D., Hoshida Y., et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100 (2008) 815-825
12. Tomlins S.A., Laxman B., Varambally S., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10 (2008) 177-188
13. Tomlins S.A., Mehra R., Rhodes D.R., et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39 (2007) 41-51
14. Tomlins S.A., Rhodes D.R., Yu J., et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13 (2008) 519-528
15. Jhavar S., Brewer D., Edwards S., et al. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int 103 (2009) 1256-1269
16. Attard G., Clark J., Ambroisine L., et al. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer 99 (2008) 314-320
17. Hermans K.G., Bressers A.A., van der Korput H.A., Dits N.F., Jenster G., and Trapman J. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res 68 (2008) 3094-3098
18. Hermans K.G., van der Korput H.A., van Marion R., et al. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 68 (2008) 7541-7549
19. Tomlins S.A., Laxman B., Dhanasekaran S.M., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448 (2007) 595-599
20. Kumar-Sinha C., Tomlins S.A., and Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8 (2008) 497-511
21. Mehra R., Tomlins S.A., Shen R., et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20 (2007) 538-544
22. Dai M.J., Chen L.L., Zheng Y.B., et al. Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer [in Chinese]. Zhonghua Yi Xue Za Zhi 88 (2008) 669-673
23. Darnel A.D., Lafargue C.J., Vollmer R.T., Corcos J., and Bismar T.A. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther 8 (2009) 125-130
24. Furusato B., Gao C.L., Ravindranath L., et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 21 (2008) 67-75
25. Lu Q., Nunez E., Lin C., et al. A sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants. Nucleic Acids Res 36 (2008) e130
26. Rouzier C., Haudebourg J., Carpentier X., et al. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Cancer Genet Cytogenet 183 (2008) 21-27
27. Saramaki O.R., Harjula A.E., Martikainen P.M., Vessella R.L., Tammela T.L., and Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14 (2008) 3395-3400
28. Yoshimoto M., Joshua A.M., Cunha I.W., et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 21 (2008) 1451-1460
29. Gopalan A., Leversha M.A., Satagopan J.M., et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69 (2009) 1400-1406
30. Demichelis F., Fall K., Perner S., et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26 (2007) 4596-4599
31. Attard G., Clark J., Ambroisine L., et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27 (2008) 253-263
32. FitzGerald L.M., Agalliu I., Johnson K., et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 8 (2008) 230
33. Teixeira M.R. Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions. Am J Surg Pathol 32 (2008) 642-644 author reply 4
34. Tu J.J., Rohan S., Kao J., Kitabayashi N., Mathew S., and Chen Y.T. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 20 (2007) 921-928
35. Rajput A.B., Miller M.A., De Luca A., et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 60 (2007) 1238-1243
36. Perner S., Mosquera J.M., Demichelis F., et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31 (2007) 882-888
37. Mehra R., Han B., Tomlins S.A., et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 67 (2007) 7991-7995
38. Liu W., Ewing C.M., Chang B.L., et al. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer 46 (2007) 972-980
39. Barry M., Perner S., Demichelis F., and Rubin M.A. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 70 (2007) 630-633
40. Yoshimoto M., Joshua A.M., Chilton-Macneill S., et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 8 (2006) 465-469
41. Perner S., Demichelis F., Beroukhim R., et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66 (2006) 8337-8341
42. Clark J., Merson S., Jhavar S., et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26 (2007) 2667-2673
43. Hu Y., Dobi A., Sreenath T., et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 14 (2008) 4719-4725
44. Lapointe J., Kim Y.H., Miller M.A., et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 20 (2007) 467-473
45. Wang J., Cai Y., Ren C., and Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66 (2006) 8347-8351
46. Wang J., Cai Y., Yu W., Ren C., Spencer D.M., and Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 68 (2008) 8516-8524
47. Cerveira N., Ribeiro F.R., Peixoto A., et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8 (2006) 826-832
48. Clark J., Attard G., Jhavar S., et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27 (2008) 1993-2003
49. Mosquera J.M., Perner S., Genega E.M., et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 14 (2008) 3380-3385
50. Klezovitch O., Risk M., Coleman I., et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 105 (2008) 2105-2110
51. Sun C., Dobi A., Mohamed A., et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27 (2008) 5348-5353
52. Mehra R., Tomlins S.A., Yu J., et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68 (2008) 3584-3590
53. Attard G., Reid A.H., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26 (2008) 4563-4571
54. Meiers I., Waters D.J., and Bostwick D.G. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. Urology 70 (2007) 3-8
55. Bjartell A. PSA and prostate cancer screening: the challenge of the new millennium. Eur Urol 52 (2007) 1284-1286
56. Etzioni R. Statistical issues in the evaluation of screening and early detection modalities. Urol Oncol 26 (2008) 308-315
57. Lilja H., Ulmert D., and Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8 (2008) 268-278
58. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320-1328
59. Andriole G.L., Grubb III R.L., Buys S.S., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 (2009) 1310-1319
60. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999) 5975-5979
61. Marks L.S., and Bostwick D.G. Prostate cancer specificity of PCA3 gene testing: examples from clinical practice. Rev Urol 10 (2008) 175-181
62. Laxman B., Tomlins S.A., Mehra R., et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8 (2006) 885-888
63. Laxman B., Morris D.S., Yu J., et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68 (2008) 645-649
64. Hessels D., Smit F.P., Verhaegh G.W., Witjes J.A., Cornel E.B., and Schalken J.A. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 13 (2007) 5103-5108
65. Ahyai S.A., Graefen M., Steuber T., et al. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. Eur Urol 53 (2008) 750-757
66. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
67. Cheville J.C., Karnes R.J., Therneau T.M., et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 26 (2008) 3930-3936
68. Nam R.K., Sugar L., Wang Z., et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 6 (2007) 40-45
69. Nam R.K., Sugar L., Yang W., et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 97 (2007) 1690-1695
70. Porter C.R., Kodama K., Gibbons R.P., et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 176 (2006) 569-574
71. Marcucci G., Baldus C.D., Ruppert A.S., et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 23 (2005) 9234-9242
72. Attard G., Sarker D., Reid A., Molife R., Parker C., and de Bono J.S. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 95 (2006) 767-774
73. Chen Y., Sawyers C.L., and Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8 (2008) 440-448
74. Attard G., Swennenhuis J.F., Olmos D., et al. Characterization of ERG, AR, and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69 (2009) 2912-2918
75. Hermans K.G., van Marion R., van Dekken H., Jenster G., van Weerden W.M., and Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66 (2006) 10658-10663
76. Stegmaier K., Wong J.S., Ross K.N., et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 4 (2007) e122
77. Bumcrot D., Manoharan M., Koteliansky V., and Sah D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2 (2006) 711-719
78. Smith R., Owen L.A., Trem D.J., et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 9 (2006) 405-416
79. Bashir A., Volik S., Collins C., Bafna V., and Raphael B.J. Evaluation of paired-end sequencing strategies for detection of genome rearrangements in cancer. PLoS Comput Biol 4 (2008) e1000051
80. Campbell P.J., Stephens P.J., Pleasance E.D., et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 40 (2008) 722-729
81. Hofer M.D., Kuefer R., Maier C., et al. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer. Cancer Res 69 (2009) 640-646
82. Ng P., Tan J.J., Ooi H.S., et al. Multiplex sequencing of paired-end ditags (MS-PET): a strategy for the ultra-high-throughput analysis of transcriptomes and genomes. Nucleic Acids Res 34 (2006) e84
83. Raphael B.J., Volik S., Yu P., et al. A sequence-based survey of the complex structural organization of tumor genomes. Genome Biol 9 (2008) R59
84. Sreekumar A., Poisson L.M., Rajendiran T.M., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457 (2009) 910-914